Immunogenicity and Safety of a Single Dose or Two Doses Given 28 Days Apart of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Subjects Aged 6 Months or Older in India

Trial Profile

Immunogenicity and Safety of a Single Dose or Two Doses Given 28 Days Apart of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Subjects Aged 6 Months or Older in India

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors Sanofi
  • Most Recent Events

    • 22 Jun 2017 Status changed from recruiting to completed.
    • 03 Feb 2016 Planned End Date changed from 1 Nov 2016 to 1 Aug 2017, according to ClinicalTrials.gov record.
    • 03 Feb 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Feb 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top